Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

Background AKT pathway activation is implicated in endocrine-therapy resistance. Data on
the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy …

PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …

Background An improvement in progression-free survival was shown with trastuzumab
deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast …

Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in
human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We …

Background Trastuzumab emtansine is the current standard treatment for patients with
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …

PURPOSE Hormone receptor–positive (HR+) human epidermal growth factor receptor 2–
negative (HER2–) endocrine-resistant metastatic breast cancer is treated with sequential …

Background In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan
showed robust activity in patients with HER2-positive metastatic breast cancer who were …